Evidence map›Paper›PMID 36914634›Full record

ArticleNature communications2023

Reference compounds for characterizing cellular injury in high-content cellular morphology assays.

Jayme L Dahlin, Bruce K Hua, Beth E Zucconi, Shawn D Nelson, Shantanu Singh, Anne E Carpenter, Jonathan H Shrimp, Evelyne Lima-Fernandes, Mathias J Wawer, Lawrence P W Chung and 16 more

Open access · goldFull text read
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
13.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. The OASIS Consortium: integrating multi-omics technologies to transform chemical safety assessment.Toxicological sciences : an official journal of the Society of Toxicology · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Targeting lysine acetylation readers and writers.Nature reviews. Drug discovery · 2025
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 8 institutions in 3 countries.

Jayme L Dahlin *National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA. jaymedahlin@gmail.com.ORCID 0000-0003-4151-9944
Bruce K Hua *Chemical Biology and Therapeutics Science Program, Broad Institute, Cambridge, MA, USA.ORCID 0000-0002-7330-2312
Beth E ZucconiDivision of Genetics, Departments of Medicine and Biological Chemistry and Molecular Pharmacology, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.
Shawn D NelsonStanley Center, Broad Institute, Cambridge, MA, USA.
Shantanu SinghImaging Platform, Broad Institute, Cambridge, MA, USA.ORCID 0000-0003-3150-3025
Anne E CarpenterImaging Platform, Broad Institute, Cambridge, MA, USA.ORCID 0000-0003-1555-8261
Jonathan H ShrimpChemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.ORCID 0000-0001-9872-942X
Evelyne Lima-FernandesStructural Genomics Consortium, University of Toronto, Toronto, ON, Canada.
Mathias J WawerChemical Biology and Therapeutics Science Program, Broad Institute, Cambridge, MA, USA.ORCID 0000-0001-6664-0930
Lawrence P W ChungChemical Biology and Therapeutics Science Program, Broad Institute, Cambridge, MA, USA.
Ayushi AgrawalChemical Biology and Therapeutics Science Program, Broad Institute, Cambridge, MA, USA.ORCID 0000-0003-2940-8926
Mary O'ReillyPattern, Broad Institute, Cambridge, MA, USA.
Dalia Barsyte-LovejoyStructural Genomics Consortium, University of Toronto, Toronto, ON, Canada.ORCID 0000-0002-6560-9621
Magdalena SzewczykStructural Genomics Consortium, University of Toronto, Toronto, ON, Canada.
Fengling LiStructural Genomics Consortium, University of Toronto, Toronto, ON, Canada.
Parnian LakDepartment of Pharmaceutical Chemistry and Quantitative Biology Institute, University of California San Francisco, San Francisco, CA, USA.
Matthew CuellarInstitute for Therapeutics Discovery and Development, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0003-3365-2120
Philip A ColeDivision of Genetics, Departments of Medicine and Biological Chemistry and Molecular Pharmacology, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.ORCID 0000-0001-6873-7824
Jordan L MeierChemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.ORCID 0000-0002-0537-7101
Tim ThomasDepartment of Medical Biology, University of Melbourne, Parkville, VIC, Australia.ORCID 0000-0002-7623-8344
Jonathan B BaellMedicinal Chemistry Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.ORCID 0000-0003-2114-8242
Peter J BrownStructural Genomics Consortium, University of Toronto, Toronto, ON, Canada.ORCID 0000-0002-8454-0367
Michael A WaltersInstitute for Therapeutics Discovery and Development, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0001-5650-9277
Paul A ClemonsChemical Biology and Therapeutics Science Program, Broad Institute, Cambridge, MA, USA.ORCID 0000-0002-1800-5112
Stuart L SchreiberChemical Biology and Therapeutics Science Program, Broad Institute, Cambridge, MA, USA.
Bridget K WagnerChemical Biology and Therapeutics Science Program, Broad Institute, Cambridge, MA, USA. bwagner@broadinstitute.org.ORCID 0000-0002-2629-361X
Broad Institute · USUniversity of Toronto · CABrigham and Women's Hospital · USNational Institutes of Health · USUniversity of Minnesota · USMonash University · AUQB3 · USThe University of Melbourne · AU

Funding

Targeting Cancer Through Modifications and MetabolismZIABC011488 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MEIER, JORDAN L · 2013 to 2025
$21.3M
VASCULAR, PULMONARY AND RENAL INJURYT32HL007627 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI GIMBRONE, MICHAEL A, MITCHELL, RICHARD N · 1985 to 2019
$12.7M
Development and Testing of New Computational Methods for Ligand Discovery and MechanismR35GM122481 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Brian K Shoichet · 2017 to 2026
$8.5M
Extracting rich information from biological imagesR35GM122547 · NIGMS · BROAD INSTITUTE, INC. · PI Anne E. Carpenter · 2017 to 2026
$6.2M
Targeting vulnerabilities of therapy-resistant cancer cell states with small moleculesU01CA217848 · NCI · BROAD INSTITUTE, INC. · PI SCHREIBER, STUART L · 2017 to 2021
$5.8M
Protein Acylation and Methylation Mechanisms_Administrative SupplementR37GM062437 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI COLE, PHILIP A · 2013 to 2022
$4.1M
Studies of Materials with Physiological PropertiesR35GM127045 · NIGMS · BROAD INSTITUTE, INC. · PI SCHREIBER, STUART L · 2018 to 2022
$3.2M
One-compound, one-islet: A high-throughput platform for small-molecule discoveryU01DK123717 · NIDDK · BROAD INSTITUTE, INC. · PI KULKARNI, ROHIT N., WAGNER, BRIDGET K · 2019 to 2022
$3.1M
Chemical Approaches to Understanding Reversible Lysine ModificationsR35GM149229 · NIGMS · BRIGHAM AND WOMEN'S HOSPITAL · PI PHILIP A COLE · 2023 to 2026
$1.9M
Translating novel cancer targets and mechanisms from the CTD^2 Network using molecular gluesU01CA272612 · NCI · BROAD INSTITUTE, INC. · PI CLEMONS, PAUL ANDREW, SCHREIBER, STUART L · 2022 to 2023
$1.9M
Opera Phenix high-throughput microplate confocal imager for high-content screeningS10OD026839 · OD · BROAD INSTITUTE, INC. · PI WAGNER, BRIDGET K · 2019 to 2019
$1.0M
p300/CBP and MOZ Acetyltransferase Function and Substrate SelectivityK99GM124357 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI ZUCCONI, BETH · 2017 to 2018
$180k
NCI NIH HHS U01 CA217848NCI NIH HHS U01 CA272612NHLBI NIH HHS T32 HL007627NIDDK NIH HHS U01 DK123717NIGMS NIH HHS K99 GM124357NIGMS NIH HHS R35 GM122481NIGMS NIH HHS R35 GM122547NIGMS NIH HHS R35 GM127045NIGMS NIH HHS R35 GM149229NIGMS NIH HHS R37 GM062437NIH HHS S10 OD026839Wellcome Trust
6 · The paper itself

Abstract

Robust, generalizable approaches to identify compounds efficiently with undesirable mechanisms of action in complex cellular assays remain elusive. Such a process would be useful for hit triage during high-throughput screening and, ultimately, predictive toxicology during drug development. Here we generate cell painting and cellular health profiles for 218 prototypical cytotoxic and nuisance compounds in U-2 OS cells in a concentration-response format. A diversity of compounds that cause cellular damage produces bioactive cell painting morphologies, including cytoskeletal poisons, genotoxins, nonspecific electrophiles, and redox-active compounds. Further, we show that lower quality lysine acetyltransferase inhibitors and nonspecific electrophiles can be distinguished from more selective counterparts. We propose that the purposeful inclusion of cytotoxic and nuisance reference compounds such as those profiled in this resource will help with assay optimization and compound prioritization in complex cellular assays like cell painting.

Indexed as

High-Throughput Screening AssaysOxidation-Reduction

Identifiers

PMID36914634
PMCPMC10011410
OpenAlexW4324128767

What Socratic holds

Textfull text, public
LicenceCC BY
measurements read133
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.